ELOVL2 and prostate carcinoma: There is one study where in the human prostate cancer cell line (LNCaP) with the knockdown of ELOVL2, ELOVL5, or ELOVL7, no compensatory increases in the expression of the other ELOVLs were observed in the cancer cell line, and no normal cell line was analyzed [44].